Yu-Rui Jiao1, Wei Wang2, Peng-Cheng Lei3, Hui-Ping Jia4, Jie Dong5, Yun-Qian Gou3, Cheng-Long Chen6, Jie Cao7, Ya-Feng Wang8, Yi-Kun Zhu9. 1. Dept of Endocrinology, Second Clinical Medical College, Shanxi Medical University, Taiyuan 030001, China; Chengdu University of Technology, College of Management Science, Chengdu 610051, China. 2. School of Mathematical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China. 3. Chengdu University of Technology, College of Management Science, Chengdu 610051, China. 4. School of International Pharmaceutical Business, China Pharmaceutical University, Jiangsu, China. 5. Economics and Business Administration College, Chongqing University, Chongqing 400044, China. 6. Dept of Orthopedic Surgery, Second Clinical Medical College, Shanxi Medical University, Taiyuan 030001, China. 7. Dept of Endocrinology, Second Clinical Medical College, Shanxi Medical University, Taiyuan 030001, China. 8. Chengdu University of Technology, College of Management Science, Chengdu 610051, China; Xi'an Jiao Tong University Health Science Center, Xi'an 710061, China. 9. Dept of Endocrinology, Second Clinical Medical College, Shanxi Medical University, Taiyuan 030001, China. Electronic address: zyk1003@sxmu.edu.cn.
Abstract
BACKGROUND: The influence of 5-HTT, BMPR2, EDN1, ENG, KCNA5 genes polymorphisms on susceptibility of pulmonary arterial hypertension remains uncertain. This meta-analysis is conducted for further study. METHODS: We conducted a literature search on PubMed and ISI web of science databases for searching relevant articles until November 2017. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. A total of 17 articles with 2631 PAH subjects and 5139 controls were included in the final meta-analysis. Statistical software Stata13.0 was used for data-analysis. RESULTS: A significant relationship was found between the 5-HTT L/S polymorphism and PAH in all the genetic models [LL vs. SS: OR = 1.60, 95% CI, 1.11-2.32; LS vs. SS: OR = 1.55, 95% CI, 1.10-2.21; (LS + LL) vs. SS: OR = 1.56, 95% CI, 1.13-2.17; L vs. S: OR = 1.32, 95% CI, 1.08-1.62]. There were also associations of the SERT L/S polymorphism with IPAH and PAH in COPD [IPAH L/S: OR = 1.26, 95% CI, 1.01-1.57; PAH in COPD L/S: OR = 1.42, 95% CI, 1.04-1.94]. In addition, the results showed a statistically significant association between EDN1 rs5370 polymorphism and the risk of PAH in all the genetic models [TT vs. GG: OR = 3.32, 95% CI, 1.30-8.51; TG vs. GG: OR = 2.68, 95% CI, 1.54-4.66; (TG + TT) vs. GG: OR = 2.82, 95% CI, 1.69-4.71; T vs. G: OR = 2.43, 95% CI, 1.60-3.68]. However, the significant association was not found between BMPR2 rs1061157, KCNA5 rs10744676, ENG rs3739817 polymorphisms and the risk of PAH (all p > 0.05). CONCLUSIONS: 5-HTT L/S polymorphism and END1 rs5370 polymorphism were correlated with significantly increased risk of PAH. Moreover, L allele in 5-HTT gene increased susceptibility to IPAH and PAH in COPD.
BACKGROUND: The influence of 5-HTT, BMPR2, EDN1, ENG, KCNA5 genes polymorphisms on susceptibility of pulmonary arterial hypertension remains uncertain. This meta-analysis is conducted for further study. METHODS: We conducted a literature search on PubMed and ISI web of science databases for searching relevant articles until November 2017. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. A total of 17 articles with 2631 PAH subjects and 5139 controls were included in the final meta-analysis. Statistical software Stata13.0 was used for data-analysis. RESULTS: A significant relationship was found between the 5-HTT L/S polymorphism and PAH in all the genetic models [LL vs. SS: OR = 1.60, 95% CI, 1.11-2.32; LS vs. SS: OR = 1.55, 95% CI, 1.10-2.21; (LS + LL) vs. SS: OR = 1.56, 95% CI, 1.13-2.17; L vs. S: OR = 1.32, 95% CI, 1.08-1.62]. There were also associations of the SERT L/S polymorphism with IPAH and PAH in COPD [IPAH L/S: OR = 1.26, 95% CI, 1.01-1.57; PAH in COPD L/S: OR = 1.42, 95% CI, 1.04-1.94]. In addition, the results showed a statistically significant association between EDN1rs5370 polymorphism and the risk of PAH in all the genetic models [TT vs. GG: OR = 3.32, 95% CI, 1.30-8.51; TG vs. GG: OR = 2.68, 95% CI, 1.54-4.66; (TG + TT) vs. GG: OR = 2.82, 95% CI, 1.69-4.71; T vs. G: OR = 2.43, 95% CI, 1.60-3.68]. However, the significant association was not found between BMPR2rs1061157, KCNA5rs10744676, ENGrs3739817 polymorphisms and the risk of PAH (all p > 0.05). CONCLUSIONS:5-HTT L/S polymorphism and END1rs5370 polymorphism were correlated with significantly increased risk of PAH. Moreover, L allele in 5-HTT gene increased susceptibility to IPAH and PAH in COPD.
Authors: Mark A Oyama; Chad Elliott; Kerry A Loughran; Alexander P Kossar; Estibaliz Castillero; Robert J Levy; Giovanni Ferrari Journal: Cardiovasc Pathol Date: 2020-01-07 Impact factor: 2.185
Authors: Mercedes Garzon-Martinez; Nuria Perretta-Tejedor; Luis Garcia-Ortiz; Manuel A Gomez-Marcos; Rogelio Gonzalez-Sarmiento; Francisco J Lopez-Hernandez; Carlos Martinez-Salgado Journal: Sci Rep Date: 2020-06-10 Impact factor: 4.379